Target Engagement for Intranasal Oxytocin in Autism Spectrum Disorders, an fMRI Dose Response Study

Trial Profile

Target Engagement for Intranasal Oxytocin in Autism Spectrum Disorders, an fMRI Dose Response Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Aug 2018

At a glance

  • Drugs Oxytocin (Primary)
  • Indications Pervasive child development disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Aug 2018 Planned End Date changed from 1 Jul 2018 to 1 Sep 2018.
    • 07 Aug 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Sep 2018.
    • 01 Jun 2018 Planned End Date changed from 30 Mar 2019 to 1 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top